Connect to other sites within the UBM Medica Network
FDA Approves Drug Combo for Gastric/GEJ Adenocarcinoma
The FDA approved ramucirumab (Cyramza) in combination with paclitaxel for treating patients with advanced gastric or gastroesophageal junction adenocarcinoma.
MicroRNA Expression Predictive of Outcomes in Esophageal Cancer
Measuring expression of several microRNAs were significantly predictive of complete pathologic response to treatment in patients with esophageal adenocarcinoma.
Best to Stage Esophageal Cancer After Neoadjuvant Chemo
The stage of esophageal adenocarcinomas after neoadjuvant chemotherapy is predictive of outcomes, rather than the stage determined prior to therapy.
Gene Mutation Test Could Aid Esophageal Cancer Diagnosis
New research has identified specific gene mutations that occur in precancerous esophageal lesions, a finding which was then put into use with a simple non-endoscopic test.
Preop Chemoradiation Fails to Improve Survival in Early Esophageal Cancer
Neoadjuvant chemoradiotherapy did not improve resection rates or survival outcomes in patients with early-stage, locally advanced esophageal cancer.
PET/MR Could Be Effective for Staging Esophageal Cancer
Preoperative staging of esophageal cancer with PET/MR is approximately as good as with endoscopic ultrasound, and may improve slightly over ultrasound and PET/CT scans, according to a new study.
EGJ and Esophageal Cancers: Choosing Induction Therapy so as to Err on the Side of Overtreatment Rather Than Undertreatment When Staging Is Imperfect
Until anatomic staging and physiologic prediction models improve, induction therapy serves as a useful crutch that can mitigate the weaknesses in both of these important preoperative tasks.
By clicking Accept, you agree to become a member of the UBM Medica Community.